文献

J-GLOBAL ID：202202247118346854   整理番号：22A0215154

腫瘍DNA-メチローム由来エピジェネティックフィンガープリントは術後放射線化学療法後の局所再発のリスクでHPV陰性頭頸部患者を同定する【JST・京大機械翻訳】

Tumor DNA-methylome derived epigenetic fingerprint identifies HPV-negative head and neck patients at risk for locoregional recurrence after postoperative radiochemotherapy

著者 (113件)： Tawk Bouchra (German Cancer Research Center (DKFZ), Heidelberg, Germany) ,  Tawk Bouchra (German Cancer Consortium (DKTK), Core Center Heidelberg, Heidelberg, Germany) ,  Tawk Bouchra (Clinical Cooperation Unit Translational Radiation Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital (UKHD), Heidelberg, Germany) ,  Tawk Bouchra (Division of Molecular and Translational Radiation Oncology, Department of Radiation Oncology, Heidelberg Faculty of Medicine (MFHD) and Heidelberg University Hospital (UKHD), Heidelberg Ion-Beam Therapy Center (HIT), Heidelberg, Germany) ,  Tawk Bouchra (Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Oncology (NCRO), Heidelberg University, Heidelberg, Germany) ,  Wirkner Ute (German Cancer Research Center (DKFZ), Heidelberg, Germany) ,  Wirkner Ute (German Cancer Consortium (DKTK), Core Center Heidelberg, Heidelberg, Germany) ,  Wirkner Ute (Clinical Cooperation Unit Translational Radiation Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital (UKHD), Heidelberg, Germany) ,  Wirkner Ute (Division of Molecular and Translational Radiation Oncology, Department of Radiation Oncology, Heidelberg Faculty of Medicine (MFHD) and Heidelberg University Hospital (UKHD), Heidelberg Ion-Beam Therapy Center (HIT), Heidelberg, Germany) ,  Wirkner Ute (Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Oncology (NCRO), Heidelberg University, Heidelberg, Germany) ,  Schwager Christian (German Cancer Research Center (DKFZ), Heidelberg, Germany) ,  Schwager Christian (German Cancer Consortium (DKTK), Core Center Heidelberg, Heidelberg, Germany) ,  Schwager Christian (Clinical Cooperation Unit Translational Radiation Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital (UKHD), Heidelberg, Germany) ,  Schwager Christian (Division of Molecular and Translational Radiation Oncology, Department of Radiation Oncology, Heidelberg Faculty of Medicine (MFHD) and Heidelberg University Hospital (UKHD), Heidelberg Ion-Beam Therapy Center (HIT), Heidelberg, Germany) ,  Schwager Christian (Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Oncology (NCRO), Heidelberg University, Heidelberg, Germany) ,  Rein Katrin (German Cancer Research Center (DKFZ), Heidelberg, Germany) ,  Rein Katrin (German Cancer Consortium (DKTK), Core Center Heidelberg, Heidelberg, Germany) ,  Rein Katrin (Clinical Cooperation Unit Translational Radiation Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital (UKHD), Heidelberg, Germany) ,  Rein Katrin (Division of Molecular and Translational Radiation Oncology, Department of Radiation Oncology, Heidelberg Faculty of Medicine (MFHD) and Heidelberg University Hospital (UKHD), Heidelberg Ion-Beam Therapy Center (HIT), Heidelberg, Germany) ,  Rein Katrin (Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Oncology (NCRO), Heidelberg University, Heidelberg, Germany) ,  Zaoui Karim (Department of Otorhinolaryngology, Head and Neck Surgery, Heidelberg University Hospital, Heidelberg, Germany) ,  Federspil Philippe A. (Department of Otorhinolaryngology, Head and Neck Surgery, Heidelberg University Hospital, Heidelberg, Germany) ,  Adeberg Sebastian (German Cancer Research Center (DKFZ), Heidelberg, Germany) ,  Adeberg Sebastian (German Cancer Consortium (DKTK), Core Center Heidelberg, Heidelberg, Germany) ,  Adeberg Sebastian (Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany) ,  Adeberg Sebastian (Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany) ,  Linge Annett (Clinical Cooperation Unit Translational Radiation Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital (UKHD), Heidelberg, Germany) ,  Linge Annett (German Cancer Consortium (DKTK), Partner Site Dresden, Dresden, Germany) ,  Linge Annett (Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany) ,  Linge Annett (OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany) ,  Linge Annett (National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany) ,  Linge Annett (Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany) ,  Linge Annett (Helmholtz Association/Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany) ,  Ganswindt Ute (German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany) ,  Ganswindt Ute (Department of Radiation Oncology, Medical University of Innsbruck, Innsbruck, Austria) ,  Hess Julia (Department of Radiation Oncology, University Hospital Ludwig-Maximilians-University of Munich, Munich, Germany) ,  Hess Julia (Research Unit Radiation Cytogenetics, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health GmbH, Neuherberg, Germany) ,  Hess Julia (Clinical Cooperation Group “Personalized Radiotherapy in Head and Neck Cancer”, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health GmbH, Neuherberg, Germany) ,  Unger Kristian (Department of Radiation Oncology, University Hospital Ludwig-Maximilians-University of Munich, Munich, Germany) ,  Unger Kristian (Research Unit Radiation Cytogenetics, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health GmbH, Neuherberg, Germany) ,  Unger Kristian (Clinical Cooperation Group “Personalized Radiotherapy in Head and Neck Cancer”, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health GmbH, Neuherberg, Germany) ,  Tinhofer Ingeborg (German Cancer Consortium (DKTK), Partner Site Berlin, Berlin, Germany) ,  Tinhofer Ingeborg (Department of Radiooncology and Radiotherapy, Charite University Hospital, Berlin, Germany) ,  Budach Volker (German Cancer Consortium (DKTK), Partner Site Berlin, Berlin, Germany) ,  Budach Volker (Department of Radiooncology and Radiotherapy, Charite University Hospital, Berlin, Germany) ,  Lohaus Fabian (Clinical Cooperation Unit Translational Radiation Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital (UKHD), Heidelberg, Germany) ,  Lohaus Fabian (German Cancer Consortium (DKTK), Partner Site Dresden, Dresden, Germany) ,  Lohaus Fabian (Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany) ,  Lohaus Fabian (OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany) ,  Lohaus Fabian (National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany) ,  Lohaus Fabian (Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany) ,  Lohaus Fabian (Helmholtz Association/Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany) ,  Krause Mechthild (Clinical Cooperation Unit Translational Radiation Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital (UKHD), Heidelberg, Germany) ,  Krause Mechthild (German Cancer Consortium (DKTK), Partner Site Dresden, Dresden, Germany) ,  Krause Mechthild (Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany) ,  Krause Mechthild (OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany) ,  Krause Mechthild (National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany) ,  Krause Mechthild (Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany) ,  Krause Mechthild (Helmholtz Association/Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany) ,  Guberina Maja (German Cancer Consortium (DKTK), Partner Site Essen, Essen, Germany) ,  Guberina Maja (Department of Radiotherapy, Medical Faculty, University of Duisburg-Essen, Essen, Germany) ,  Stuschke Martin (Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany) ,  Stuschke Martin (Department of Radiotherapy, Medical Faculty, University of Duisburg-Essen, Essen, Germany) ,  Balermpas Panagiotis (German Cancer Consortium (DKTK), Partner Site Frankfurt, Frankfurt, Germany) ,  Balermpas Panagiotis (Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland) ,  Rodel Claus (German Cancer Consortium (DKTK), Partner Site Frankfurt, Frankfurt, Germany) ,  Rodel Claus (Department of Radiotherapy and Oncology, Goethe-University Frankfurt, Frankfurt, Germany) ,  Grosu Anca L. (German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany) ,  Grosu Anca L. (Department of Radiation Oncology, Clinical Study Section, University of Freiburg, Freiburg, Germany) ,  Grosu Anca L. (Department of Radiation Oncology, University of Freiburg, Freiburg, Germany) ,  Schaefer Henning (German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany) ,  Schaefer Henning (Department of Radiation Oncology, Clinical Study Section, University of Freiburg, Freiburg, Germany) ,  Zips Daniel (German Cancer Consortium (DKTK), Partner Site Tuebingen, Tuebingen, Germany) ,  Zips Daniel (Department of Radiation Oncology, Faculty of Medicine and University Hospital Tuebingen, Eberhard Karls Universitaet Tuebingen, Tuebingen, Germany) ,  Combs Stephanie E. (German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany) ,  Combs Stephanie E. (Department of Radiation Oncology, Technische Universitaet Muenchen, Munich, Germany) ,  Pigorsch Steffi (German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany) ,  Pigorsch Steffi (Department of Radiation Oncology, Technische Universitaet Muenchen, Munich, Germany) ,  Zitzelsberger Horst (Department of Radiation Oncology, University Hospital Ludwig-Maximilians-University of Munich, Munich, Germany) ,  Zitzelsberger Horst (Research Unit Radiation Cytogenetics, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health GmbH, Neuherberg, Germany) ,  Zitzelsberger Horst (Clinical Cooperation Group “Personalized Radiotherapy in Head and Neck Cancer”, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health GmbH, Neuherberg, Germany) ,  Baumeister Philipp (Research Unit Radiation Cytogenetics, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health GmbH, Neuherberg, Germany) ,  Baumeister Philipp (Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital, Ludwig-Maximilians-University of Munich, Munich, Germany) ,  Kirchner Thomas (German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany) ,  Kirchner Thomas (Institute of Pathology, Faculty of Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany) ,  Bewerunge-Hudler Melanie (Genomics and Proteomics Core Facility, German Cancer Research Center, Heidelberg, Germany) ,  Weichert Wilko (German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany) ,  Weichert Wilko (Institute of Pathology, Technische Universitaet Muenchen, Munich, Germany) ,  Hess Jochen (Department of Otorhinolaryngology, Head and Neck Surgery, Heidelberg University Hospital, Heidelberg, Germany) ,  Hess Jochen (Department of Molecular Mechanisms of Head and Neck Tumors, German Cancer Research Center, Heidelberg, Germany) ,  Herpel Esther (German Cancer Research Center (DKFZ), Heidelberg, Germany) ,  Herpel Esther (German Cancer Consortium (DKTK), Core Center Heidelberg, Heidelberg, Germany) ,  Herpel Esther (Tissue Bank, National Center for Tumor Diseases (NCT), Heidelberg, Germany) ,  Herpel Esther (Department of Applied Tumor Biology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany) ,  Belka Claus (German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany) ,  Belka Claus (Department of Radiation Oncology, University Hospital Ludwig-Maximilians-University of Munich, Munich, Germany) ,  Belka Claus (Research Unit Radiation Cytogenetics, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health GmbH, Neuherberg, Germany) ,  Baumann Michael (German Cancer Research Center (DKFZ), Heidelberg, Germany) ,  Baumann Michael (German Cancer Consortium (DKTK), Core Center Heidelberg, Heidelberg, Germany) ,  Baumann Michael (German Cancer Consortium (DKTK), Partner Site Dresden, Dresden, Germany) ,  Baumann Michael (Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany) ,  Baumann Michael (OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany) ,  Debus Juergen (German Cancer Research Center (DKFZ), Heidelberg, Germany) ,  Debus Juergen (German Cancer Consortium (DKTK), Core Center Heidelberg, Heidelberg, Germany) ,  Debus Juergen (Clinical Cooperation Unit Translational Radiation Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital (UKHD), Heidelberg, Germany) ,  Debus Juergen (Division of Molecular and Translational Radiation Oncology, Department of Radiation Oncology, Heidelberg Faculty of Medicine (MFHD) and Heidelberg University Hospital (UKHD), Heidelberg Ion-Beam Therapy Center (HIT), Heidelberg, Germany) ,  Debus Juergen (Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Oncology (NCRO), Heidelberg University, Heidelberg, Germany) ,  Abdollahi Amir (German Cancer Research Center (DKFZ), Heidelberg, Germany) ,  Abdollahi Amir (German Cancer Consortium (DKTK), Core Center Heidelberg, Heidelberg, Germany) ,  Abdollahi Amir (Clinical Cooperation Unit Translational Radiation Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital (UKHD), Heidelberg, Germany) ,  Abdollahi Amir (Division of Molecular and Translational Radiation Oncology, Department of Radiation Oncology, Heidelberg Faculty of Medicine (MFHD) and Heidelberg University Hospital (UKHD), Heidelberg Ion-Beam Therapy Center (HIT), Heidelberg, Germany) ,  Abdollahi Amir (Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Oncology (NCRO), Heidelberg University, Heidelberg, Germany) ,  For the DKTK-ROG
資料名： International Journal of Cancer  (International Journal of Cancer)
巻： 150  号： 4  ページ： 603-616  発行年： 2022年 
JST資料番号： A0267B  ISSN： 0020-7136  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： アメリカ合衆国 (USA)  言語： 英語 (EN)

抄録/ポイント： ヒトパピローマウイルス陰性aka HPV(-)頭頚部扁平上皮癌(HNSCC)には,局所療法に関連するバイオマーカーが必要である。DNAメチル化パターンが高度に保存される前提に基づいて,著者らは,術後放射線化学療法(PORT-C)後の局所再発(LR)および全イベント進行のリスクでHPV(-)HNSCC患者を同定する信頼できてロバストなメチロームベースの分類器を開発することを試みた。訓練コホートは,ドイツ癌コンソーシアム-放射腫瘍学群(DKTK-ROG)多施設バイオマーカー試験のフレームでPORT-Cで均一に治療したHPV-DNA陰性HNSCC患者(n=128)から構成された。Illumina450Kと850K-EPICマイクロアレイ技術を用いてDNAメチル化分析を行った。分類器の性能を,腫瘍(CD3/CD8/PD-L1/PD1)の訓練セット,すなわち低酸素,5-ミクロRNA(5-miR),幹細胞遺伝子発現シグネチャおよび免疫組織化学(IHC)に基づく免疫学的特性化において研究した一連のバイオマーカーと統合した。検証は,2つのドイツセンター(n=125)からプールされたHPV(-)HNSCC患者の独立コホートで発生した。LR,遠隔転移および全生存に対する高い予後値(P<10-9)を有する38-メチル化プローブに基づくHPV(-)独立分類(HICR)を同定した。HICRは,解剖学的部位,リンパ節外包拡張(ECE)およびサイズ(Tステージ)を調整した多変量解析後に有意であった。HICRハイリスク腫瘍は,低酸素腫瘍(15-遺伝子シグネチャ)の若年患者および5-miRスコアの上昇に富んでいた。低酸素と5-miR共変量の調整後,HICRはすべてのエンドポイントを予測した。HICRは,PORT-Cで治療したHPV(-)HNSCC患者におけるLRのリスクを評価する新しい手段を提供し,これらの患者におけるバイオマーカー支援層別化および治療適応の新しい機会を開く。Copyright 2022 Wiley Publishing Japan K.K. All rights reserved. Translated from English into Japanese by JST.【JST・京大機械翻訳】

シソーラス用語： 多変量解析 ,  メチル化 ,  *DNA【核酸】 ,  遺伝子 ,  *腫瘍 ,  リンパ節 ,  層別 ,  母集団 ,  幹細胞 ,  遺伝子発現 ,  バイオマーカー
準シソーラス用語： DNAメチル化 ,  遠隔転移 ,  *局所再発 ,  *術後化学放射線療法 , 【Automatic Indexing@JST】

著者キーワード (5件)： 疾患再発 ,  DNAメチル化 ,  頭頸部癌 ,  放射線治療 ,  層状化

分類 (2件)： 耳・鼻・咽頭・喉頭の腫よう  (GQ04000E) ,  女性生殖器と胎児の腫よう  (GS04000K)

タイトルに関連する用語 (8件)： 腫瘍DNA ,  術後放射線化学療法 ,  局所再発 ,  リスク ,  HPV ,  頭頸部 ,  患者 ,  同定